Hairy cell leukaemia (HCL) remains an intriguing B‐cell malignancy defined by its distinctive “hairy” cytoplasmic projections and its unique pattern of bone marrow infiltration. Recent research has ...

Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): ...

Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve ...

Combination Therapy With Olaparib Plus Lenvatinib in a Patient With BRCA2-Mutated, Radioiodine-Refractory, Metastatic Papillary Thyroid Cancer: A Case Report The following represents disclosure ...

Bicistronic CD19/CD22-directed CAR-T cell therapy achieved high remission rates and durable responses in pediatric B-ALL patients. One-year EFS and OS rates were 75.5% and 93.5%, respectively, with ...

By Shreoshree Chakrabarty: B-Cell Acute Lymphoblastic Leukemia (B-ALL) is a rare but aggressive form of leukemia that primarily impacts adults, unlike its more common pediatric counterpart. It ...

Results from the largest report ever on young hairy cell leukemia (HCL) patients treated with standard chemotherapy — cladribine — are a mixed bag. On the one hand, a majority of the 83 patients, all ...

Scientists have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia (AML) cells, a frequently incurable form of cancer.

Colorado physicians helped research a new treatment protocol for the most common form of childhood cancer that has “instantly” changed how doctors treat pediatric leukemia — and provided a ...

Scientists in Japan have discovered a genetic "silencer" within the HTLV-1 virus that helps it stay hidden in the body, evading the immune system for decades. This silencer element essentially turns ...